MAI Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$212K Buy
12,483
+1,342
+12% +$21.4K ﹤0.01% 1784
2026
Q1
$165K Buy
11,141
+6,217
+126% +$90.9K ﹤0.01% 1562
2025
Q4
$78.5K Buy
4,924
+45
+0.9% +$638 ﹤0.01% 1773
2025
Q3
$53.9K Hold
4,879
﹤0.01% 1878
2025
Q2
$41.3K Hold
4,879
﹤0.01% 1971
2025
Q1
$39.2K Buy
+4,879
New +$39.5K ﹤0.01% 1867

Other funds holding AUPH

MAI Capital Management's AUPH Position: Q2 2026 in Review

MAI Capital Management increased its Aurinia Pharmaceuticals (AUPH) stake by 12% in Q2 2026, buying an estimated $21.4K and bringing the position to 12,483 shares worth $212K. The position accounts for ﹤0.01% of the portfolio, ranked #1784.

MAI Capital Management first reported a position in AUPH in Q1 2025 and has held it in 6 quarters since. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • MAI Capital Management held 12,483 shares of Aurinia Pharmaceuticals worth $212K as of Q2 2026.
  • MAI Capital Management bought 1,342 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $21.4K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #1784 holding.
  • MAI Capital Management first reported a position in Aurinia Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.